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 Deﬁ nition and Epidemiology 
 Pityriasis rubra pilaris (PRP) is a chronic, infl am-
matory, papulosquamous disorder of keratiniza-
tion with unknown etiology, characterized with 
affection of the body and palmoplantar (“san-
dal”) affection. It appears both in hereditary and 
in acquired form. The fi rst description of PRP is 
described by Claudius Tarral who, in 1835, pub-
lished a case report in Rayer’s  A Theoretical and 
Practical Treatise on the Diseases of the Skin of a 
patient he had seen 7 years earlier. Tarral did not 
recognize the dermatosis as a distinct entity, and 
it was listed under the title of “general 
psoriasis.” 
 It affects both sex male and female equally 
without sexual predilection. The highest inci-
dence is in the fi rst and sixth decade. Incidence is 
around 1:5,000. There may be racial variation as 
the incidence of classical PRP was reported to be 
closer to 1 in 50,000 in India. 
 The etiology is unknown. There are some 
similarities with psoriasis, but it is a distinct dis-
ease, which is more of a disorder of keratiniza-
tion than an infl ammatory disease. There are 
some clinical and histological evidence as well 
about vitamin A defi ciency. Infective etiology 
and familial distribution are also suggested. PRP 
could appear also after drug therapy and the 
infl uence of some triggering factors, such as 
severe infection, especially in juvenile form. 
Simultaneously PRP may appear with other 
immunological disorders, like rheumatoid 
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 Key Points 
•  Pityriasis rubra pilaris (PRP) is a chronic 
papulosquamous disorder of keratiniza-
tion. The etiology is unknown. PRP 
shows similarities with psoriasis, but it 
is a distinct disease. 
•  According to Griffi ths, there are six 
types of PRP. It appears in adults but 
also in a juvenile form. It typically 
affects extensor parts of the body, start-
ing usually from the face. Typical lesion 
is hyperkeratotic papule. Spearing 
islands of the non-affected skin are a 
pathognomonic sign. After some time, 
salmon-like discoloration of the skin 
occurs. Palmoplantar keratoderma is 
almost always present. 
•  Histology is not confi rmatory. 
•  PRP should be distinguished from psoria-
sis and other papulosquamous disorders. 
•  Treatment is topical or systemic. Retinoids 
are fi rst-line treatment. Biologics are a 
new class of available medications for the 
treatment of PRP, basically used with suc-
cess in psoriasis. 
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arthritis, and some malignancies like leukemia 
or Sezary syndrome, which indicates association 
with immunosuppression. 
 Classiﬁ cation 
 According to Griffi ths there are six types of PRP 
(Table  77.1 ) and the classical adult type is the 
most common, and it has the best prognosis. 
Remission is appearing after several years. Type 
2 PRP is the atypical adult form with a tendency 
to become chronic. The type 3 classical inher-
ited variant seems to have also good prognosis. 
Type 6 is described recently in which PRP is 
associated with HIV and this type has a poor 
prognosis.
 1.  Classical adult. Commonest type (50 % of 
cases). Spreads caudally. The patient is usu-
ally erythrodermic with diffuse thickening of 
the palms and soles. Ectropion often is 
present. 
 2.  Atypical adult. Long duration. Involves a 
more ichthyosiform pattern in association 
with hair loss and areas of eczematous 
changes. 
 3.  Classical juvenile. Similar to type 1 but affects 
children in the fi rst decade. 
 4.  Circumscribed juvenile. Affects children, 
with sharply demarcated areas of follicular 
hyperkeratosis and erythema on the knees and 
elbows. Usually does not progress. 
 5.  Atypical juvenile. Appears in the fi rst few 
years of life and is chronic. Characterized by 
follicular hyperkeratosis, whereas erythema is 
not a prominent feature. The skin on the hands 
and feet can appear scleroderma-like. 
 6.  HIV related. Symmetrical, pruritic eruption 
composed of erythematous papules is associ-
ated with late-onset acne conglobata. 
 Clinical Presentation 
 Clinical picture is the basis for establishing the 
diagnosis of PRP. 
 Classical disease begins on the face, with 
scaling and erythema, and on lateral parts of the 
neck and trunk. Also, the disease may appear on 
 extensor surface of the extremities and espe-
cially on the back of the fi rst and second pha-
lange. PRP is starting with small plaque lesions 
which spread all over the body. Typical lesion is 
follicular hyperkeratotic papule. Spearing 
“islands” of not affected skin are a pathogno-
monic sign. In 20 % of the patients, mild pruri-
tus and burning sensation are present. Also 
Koebner phenomenon may appear like in psori-
asis. After some time orange- red “salmon-like” 
discoloration of the skin is present. This is the 
hallmark for PRP. 
 Palms and soles are almost always involved, 
often showing an orange color. Palmoplantar 
waxy keratoderma appears after some period, 
with typical side spreading, producing the so- 
called sandal pattern. Changes of the nails, thick-
ened nails with a distal discoloration, and 
subungual hyperkeratosis are often present, but 
pitting of the nail and dystrophy like in psoriasis 
do not exist. 
 Erythroderma can occur after 2–3 months. 
Erythroderma is a very serious development of 
the disease and should be monitored carefully. 
However, usually PRP remains static and disap-
pears after 12 months. Mild pruritus is present. 
 Table 77.1  Classifi cation of pityriasis rubra pilaris. Griffi ths’ six types of PRP 
 Type  % of cases  Distribution  Prognosis 
 I. Classical adult  55  Generalized  Most clear in 3 years 
 II. Atypical adult  5  Generalized  Chronic 
 III. Classical juvenile  10  Generalized  Most clear in 1 year 
 IV. Circumscribed juvenile  25  Focal  Uncertain 
 V. Atypical juvenile  5  Generalized  Chronic 
 From Albert and Mackool ( 1999 ) modifi ed 
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 Histology 
 Histopathological examination is showing 
hyperkeratosis, acanthosis, and parakeratosis, 
both horizontal and vertical, and superfi cial 
perivascular lymphocytic infi ltrate. There is 
prominent follicular plugging with dense kera-
totic material. Histopathological fi ndings are 
not pathognomonic; they can exclude other pap-
ulosquamous diseases. 
 Differential Diagnosis 
 PRP has to be distinguished from psoriasis 
(which is sometimes very diffi cult) and other 
papulosquamous disorders in adults and atopic 
dermatitis in childhood. Other reasons of erythro-
derma should be excluded. Cutaneous T-cell 
lymphoma and drug skin reactions should be 
taken in consideration. 
 There is no diagnostic laboratory test to con-
fi rm PRP. Distinguishing clinical features of PRP 
include islands of normal, non-affected skin, fol-
licular keratotic plugs, and orange-red discolor-
ation of affected skin. 
 General Principles of Treatment  
 Because of the variable clinical course and low 
incidence, assessment of the treatment modali-
ties is diffi cult. Treatment modalities should 
include topical application of medications and 
systemic therapy. 
 Topical Treatments 
 Emollients are effective treatments for pityriasis 
rubra pilaris. Conservative approach is advised 
in juvenile cases. Keratolytics, like salicylic acid 
and tar, are important in the treatment. 
Calcipotriol can also be effective in children. 
Urea is very helpful. Topical corticosteroids are 
not very effective. All irritating factors should be 
avoided. Palmoplantar keratoderma is diffi cult to 
treat. Keratolytics and corticosteroids under 
occlusion are advised. Calcipotriene should be 
considered. Tazarotene is also available in the 
treatment of PRP. 
 Systemic Treatments 
 Oral synthetic retinoids are currently the treat-
ment of choice for PRP and have largely replaced 
vitamin A therapy. Oral retinoids are the fi rst 
choice in the treatment of widespread disease. 
Acitretin 0.5–1 mg/kg (in adults) or isotretinoin 
0.5–2 mg/kg is advised. Duration of treatment is 
from 3 to 6 months. The main disadvantage of 
retinoids is teratogenesis in females. Appropriate 
contraceptive measures are mandatory and preg-
nancy is absolutely contraindicated during treat-
ment with acitretin and for 2–3 years after 
discontinuation of acitretin and during treatment 
with isotretinoin and for 1 month after discon-
tinuation of isotretinoin. So, oral acitretin is not 
indicated for the treatment of women of repro-
ductive potential. 
 Methotrexate is an alternative agent for refrac-
tory PRP. Methotrexate is a second line of treat-
ment given orally 15–25 mg/weekly. 
 Use of cyclosporine in the treatment of pityri-
asis rubra pilaris is still controversial. 
 UV-light treatment uses the ultraviolet light 
spectrum of 290–400 nm to treat a variety of skin 
diseases. It can be used alone or in combination 
with other medications applied directly to the 
skin or taken orally. PUVA, Re-PUVA, is also 
applied in PRP with less success than in psoriasis 
vulgaris. UVB therapy used in psoriasis vulgaris 
could have negative infl uence and aggravate pity-
riasis rubra pilaris. 
 Oral antihistamines can be successful to 
decrease itching. 
 Oral megadoses of vitamin seem to be not so 
effective. 
 Biologics are new classes of medications that 
target immune system responses. The benefi cial 
use of biologics in psoriasis is evidence based 
and tumor necrosis factor alpha (TNF-α) has a 
central role in psoriasis. There are some data 
emphasizing that blockade of tumor necrosis fac-
tor alpha with antagonists of TNF-α also could 
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have positive effects in PRP. They are adminis-
tered by subcutaneous injection (adalimumab, 
ustekinumab, etanercept) or by intravenous infu-
sion (infl iximab). 
 In case of erythroderma, intensive supportive 
therapy is imperative. 
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